<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00531622</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10290</org_study_id>
    <secondary_id>EudraCT 2007-003159-36</secondary_id>
    <nct_id>NCT00531622</nct_id>
  </id_info>
  <brief_title>An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder</brief_title>
  <official_title>An Eight-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Saredutant 100 mg Once Daily in Combination With Escitalopram 10 mg Once Daily in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in
      combination with escitalopram 10mg once daily compared to saredutant placebo in combination
      with escitalopram 10mg once daily in patients with major depressive disorder. This study also
      includes a double-placebo group (saredutant placebo in combination with escitalopram
      placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Day 56 in Hamilton depression rating scale (HAM-D) total score</measure>
    <time_frame>Baseline, Day 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline to Day 56 in the CGI-S Severity of Illness score</measure>
    <time_frame>Baseline, Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 56 in the Clinical Global Impression (CGI) severity of illness score</measure>
    <time_frame>Baseline, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Day 56 in HAM-D depressed mood item scores.</measure>
    <time_frame>Baseline, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients demonstrating a treatment response</measure>
    <time_frame>Day 56</time_frame>
    <description>response is defined as a reduction of at least 50% in HAM-D total score between baseline and any post-baseline assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Saredudant/Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saredutant (SR48968)</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Saredudant/Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Saredudant/Escitalopram</arm_group_label>
    <arm_group_label>Placebo and Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration, capsules</description>
    <arm_group_label>Placebo and Escitalopram</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with recurrent Major Depressive Disorder

        Exclusion Criteria:

          -  Symptoms of current depressive episode for less than 30 days or more than 2 years

          -  Mild depression, as measured by standard clinical research scales

          -  Significant suicide risk

          -  Lack of sexual activity (including masturbation)

          -  Other psychiatric conditions that would obscure the results of the study

          -  History of failure to respond to antidepressant treatment

          -  Pregnancy or breast-feeding

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Finland</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <disposition_first_submitted>April 25, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 24, 2016</disposition_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Major Depressive Episode</keyword>
  <keyword>Antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

